D'Aoust T, Clocchiatti‐Tuozzo S, Rivier CA, Mishra A, Hachiya T, Grenier‐Boley B, Soumaré A, Duperron M, Le Grand Q, Bouteloup V, Proust‐Lima C, Samieri C, Neuffer J, Sargurupremraj M, Chêne G, Helmer C, Thibault M, Amouyel P, Lambert J, Kamatani Y, Jacqmin‐Gadda H, Tregouët D, Inouye M, Dufouil C, Falcone GJ, Debette S. Polygenic score integrating neurodegenerative and vascular risk informs dementia risk stratification.
Alzheimers Dement 2025;
21:e70014. [PMID:
40042447 PMCID:
PMC11881617 DOI:
10.1002/alz.70014]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2024] [Revised: 01/24/2025] [Accepted: 01/25/2025] [Indexed: 03/09/2025]
Abstract
INTRODUCTION
An integrative polygenic risk score (iPRS) capturing the neurodegenerative and vascular contribution to dementia could identify high-risk individuals and improve risk prediction.
METHODS
We developed an iPRS for dementia (iPRS-DEM) in Europeans (aged 65+), comprising genetic risk for Alzheimer's disease (AD) and 23 vascular or neurodegenerative traits (excluding apolipoprotein E [APOE]). iPRS-DEM was evaluated across cohorts comprising older community-dwelling people (N = 3702), a multi-ancestry biobank (N = 130,797 Europeans; 105,404 non-Europeans), and dementia-free memory clinic participants (N = 2032).
RESULTS
iPRS-DEM was associated with dementia risk independently of APOE in the elderly (subdistribution hazard ratio [sHR]per1SD = 1.15, 95% confidence interval [CI]: 1.03 to 1.28), which generalized to Europeans (EUR-sHRper1SD = 1.28, 95% CI: 1.09 to 1.51]), East-Asians (EAS-sHRper1SD = 5.29, 95% CI: 1.43 to 34.36), and memory-clinic participants (sHRper1SD = 1.25, 95% CI: 1.11 to 1.42). Prediction was comparable to clinical risk factors in older community-dwelling people, with improved performance among memory-clinic patients. Risk stratification was enhanced by defining four genetic risk groups with iPRS-DEM and APOE ε4, reaching five-fold increased risk in APOE ε4+/iPRS-DEM+ memory-clinic participants.
DISCUSSION
Alongside APOE ε4, iPRS-DEM may refine risk stratification for the enrichment of dementia clinical trials and prevention programs.
HIGHLIGHTS
iPRS-DEM reflects neurodegenerative and vascular contribution to dementia. We show iPRS-DEM captures additional dementia genetic risk beyond APOE and AD-PRS. iPRS-DEM, in combination with APOE ε4, shows promise for dementia risk stratification. Our results generalize across both population-based and memory-clinic settings. We show transportability of iPRS-DEM to East Asian ancestry.
Collapse